Ekspresija mamaglobina u tkivu kao prediktora agresivnosti karcinoma dojke
Sažetak
Uvod/Cilj. Humani mamaglobin je jedan od naznačajnijih markera hematogene diseminacije karcinoma dojke. Cilj rada bio je da se ukaže na važnu ulogu peritumorskog tkiva kao aktivnog učesnika u procesu tumorogeneze i koncentracije/ekspresije mamaglobina u peritumorskom tkivu kao značajnog prognostičkog faktora. Metode. Ovom studijom su bile obuhvaćene 64 bolesnice sa primarnim karcinomom dojke tokom perioda od pet godina. Za određivanje koncentracije mamaglobina A u tkivu karcinoma i peritumorskom tkivu korišćen je enzyme-linked immunosorbent assay (ELISA) test, dok je za određivanje relativne genske ekspresije ovog molekula korišćen quantitative reverse-transcription-polymerase chain reaction (qRT-PCR). Rezultati. Koncentracija mamaglobina A je rasla kako u tkivu karcinoma, tako i u peritumorskom tkivu sa porastom veličine tumora, broja zahvaćenih limfnih čvorova, broja metastaza, dok je relativna ekspresija mamaglobina A statistički bila značajno viša u karcinomu nego u peritumorskom tkivu, bez obzira na veličinu tumora, broj zahvaćenih limfnih čvorova, broj metastaza i tumorski tip. Koncentracija mamaglobina A je bila viša u peritumorskom tkivu nego u tkivu duktalnog karcinoma, dok je u slučaju lobularnog karcinoma koncentracija mamaglobina A bila veća u karcinomu, nego u peritumorskom tkivu. Zaključak. Koncentracije mamaglobina A u peritumorskom tkivu veće od 0,6704221 ng/mL i u tkivu karcinoma veće od 0,5784426 ng/mL, kao i relativna genska ekspresija mamaglobina A u tkivu karcinoma veća od 1,003 su “cut-off” vrednosti na osnovu kojih se mogu identifikovati bolesnici koji su pod povećanim rizikom od razvoja metastatske bolesti i koji se mogu tretirati ranim radikalnim adjuvantnim lečenjem.
Reference
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin 2015; 65(1): 5‒29.
Zambrano J, Yeh ES. Autophagy and Apoptotic Crosstalk: Mechanism of Therapeutic Resistance in HER2-Positive Breast Cancer. Breast Cancer (Auckl) 2016; 10: 13‒23.
Inoue K, Fry EA. Novel Molecular Markers for Breast Cancer. Biomark Cancer 2016; 8: 25‒42.
Lorincz AM, Sukumar S. Molecular links between obesity and breast cancer. Endocr Relat Cancer 2006; 13(2): 279‒92.
Toss A, Cristofanilli M. Molecular characterization and targeted therapeutic approaches in breast cancer. Breast Cancer Res 2015; 17: 60.
Koren S, Bentires-Alj M. Breast Tumor Heterogeneity: Source of Fitness, Hurdle for Therapy. Mol Cell 2015; 60(4): 537‒46.
Watson MA, Fleming TP. Mammaglobin, a mammary-specific member of the uteroglobin gene family, is overexpressed in human breast cancer. Cancer Res 1996; 56(4): 860‒5.
Lacroix M. Significance, detection and markers of disseminat-ed breast cancer cells. Endocr Relat Cancer 2006; 13(4): 1033‒67.
Watson MA, Fleming TP. Isolation of differentially expressed sequence tags from human breast cancer. Cancer Res 1994; 54(17): 4598‒602.
Bellone S, Tassi R, Betti M, English D, Cocco E, Gasparrini S, et al. Mammaglobin B (SCGB2A1) is a novel tumour antigen highly differentially expressed in all major histological types of ovarian cancer: implications for ovarian cancer immunothera-py. Br J Cancer 2013; 109(2): 462‒71.
Zafrakas M, Petschke B, Donner A, Fritzsche F, Kristiansen G, Knuchel R, et al. Expression analysis of mammaglobin A (SCGB2A2) and lipophilin B (SCGB1D2) in more than 300 human tumors and matching normal tissues reveals their co-expression in gynecologic malignancies. BMC Cancer 2006; 6: 88.
Li G, Zhang J, Jin K, He K, Wang H, Lu H, et al. Human mammaglobin: a superior marker for reverse-transcriptase PCR in detecting circulating tumor cells in breast cancer pa-tients. Biomark Med 2011; 5(2): 249‒60.
O'Brien N, Maguire TM, O'Donovan N, Lynch N, Hill AD, McDermott E, et al. Mammaglobin a: a promising marker for breast cancer. Clin Chem 2002; 48(8): 1362‒4.
Watson MA, Darrow C, Zimonjic DB, Popescu NC, Fleming TP. Structure and transcriptional regulation of the human mammaglobin gene, a breast cancer associated member of the uteroglobin gene family localized to chromosome 11q13. On-cogene 1998; 16(6): 817‒24.
Span PN, Waanders E, Manders P, Heuvel JJ, Foekens JA, Watson MA, et al. Mammaglobin is associated with low-grade, steroid receptor-positive breast tumors from postmenopausal pa-tients, and has independent prognostic value for relapse-free survival time. J Clin Oncol 2004; 22(4): 691‒8.
Lewis GH, Subhawong AP, Nassar H, Vang R, Illei PB, Park BH, et al. Relationship between molecular subtype of invasive breast carcinoma and expression of gross cystic disease fluid protein 15 and mammaglobin. Am J Clin Pathol 2011; 135(4): 587‒91.
Molecular Imaging and Contrast Agent Database (MICAD). Bethesda (MD): National Center for Biotechnology Infor-mation (US); 2004.
Mikhitarian K, Martin RH, Ruppel MB, Gillanders WE, Hoda R, Schutte del H, et al. Detection of mammaglobin mRNA in pe-ripheral blood is associated with high grade breast cancer: in-terim results of a prospective cohort study. BMC Cancer 2008; 8: 55.
Raica M, Cimpean AM, Meche A, Alexa A, Suciu C, Muresan A. Analysis of the immunohistochemical expression of mammag-lobin A in primary breast carcinoma and lymph node metasta-sis. Rom J Morphol Embryol 2009; 50(3): 341‒7.
Nunez-Villar MJ, Martinez-Arribas F, Pollan M, Lucas AR, Sanchez J, Tejerina A, et al. Elevated mammaglobin (h-MAM) expression in breast cancer is associated with clinical and bio-logical features defining a less aggressive tumour phenotype. Breast Cancer Res 2003; 5(3): R65‒70.
O'Brien N, O'Donovan N, Foley D, Hill AD, McDermott E, O'Higgins N, et al. Use of a panel of novel genes for differenti-ating breast cancer from non-breast tissues. Tumour Biol 2007; 28(6): 312‒7.
Bozhenko VK, Kharchenko NV, Vaskevich EF, Kudinova EA, Oorzhak AV, Rozhkova NI, et al. Mammaglobin in peripheral blood and tumor in breast cancer patients. Biomed Khim 2016; 62(4): 453‒7. (Russian)
Gargano G, Agnese V, Calo V, Corsale S, Augello C, Bruno L, et al. Detection and quantification of mammaglobin in the blood of breast cancer patients: can it be useful as a potential clinical marker? Preliminary results of a GOIM (Gruppo Oncologico dell'Italia Meridionale) prospective study. Ann Oncol 2006; 17 Suppl 7: vii41‒5.
Cerveira N, Torres L, Rocha P, Bizarro S, Pereira D, Abreu J, et al. Highly sensitive detection of the MGB1 transcript (mammaglobin) in the peripheral blood of breast cancer pa-tients. Int J Cancer 2004; 108(4): 592‒5.
Elston CW EI, Goulding H. Role of pathology in the prognosis and management of breast cancer. In: Elston CW, Ellis IO, edi-tors. The Breast. London: Churchill Livingstone; 1998. p. 385‒433.
Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol 2010; 17(6): 1471‒4.
Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein meas-urement with the Folin phenol reagent. J Biol Chem 1951; 193(1): 265‒75.
Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extrac-tion. Anal Biochem 1987; 162(1): 156‒9.
Bustin SA. Absolute quantification of mRNA using real-time reverse transcription polymerase chain reaction assays. J Mol Endocrinol 2000; 25(2): 169‒93.
Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc 2008; 3(6): 1101‒8.
Aristizabal-Pachon AF, de Carvalho TI, Carrara HH, de Andrade JM, Takahashi CS. Detection of human mammaglobin A mRNA in peripheral blood of breast cancer patients before treatment and association with metastasis. J Egypt Natl Canc Inst 2015; 27(4): 217‒22.
Lapeire L, Hendrix A, Lambein K, Van Bockstal M, Braems G, Van Den Broecke R, et al. Cancer-associated adipose tissue promotes breast cancer progression by paracrine oncostatin M and Jak/STAT3 signaling. Cancer Res 2014; 74(23): 6806‒19.
Trifiletti DM, Sturz VN, Showalter TN, Lobo JM. Towards deci-sion-making using individualized risk estimates for personal-ized medicine: A systematic review of genomic classifiers of solid tumors. PloS One 2017; 12(5): e0176388.
Tseng LM, Hsu NC, Chen SC, Lu YS, Lin CH, Chang DY, et al. Distant metastasis in triple-negative breast cancer. Neo-plasma 2013; 60(3): 290‒4.
Fanger GR, Houghton RL, Retter MW, Hendrickson RC, Babcook J, Dillon DC, et al. Detection of mammaglobin in the sera of patients with breast cancer. Tumour Biol 2002; 23(4): 212‒21.
Zehentner BK, Dillon DC, Jiang Y, Xu J, Bennington A, Molesh DA, et al. Application of a multigene reverse transcription-PCR assay for detection of mammaglobin and complementary transcribed genes in breast cancer lymph nodes. Clin Chem 2002; 48(8): 1225‒31.
Bernstein JL, Godbold JH, Raptis G, Watson MA, Levinson B, Aaronson SA, et al. Identification of mammaglobin as a novel serum marker for breast cancer. Clin Cancer Res 2005; 11(18): 6528‒35.
Liu Y, Ma L, Liu X, Wang L. Expression of human mammag-lobin as a marker of bone marrow micrometastasis in breast cancer. Exp Ther Med 2012; 3(3): 550‒4.
Tafreshi NK, Enkemann SA, Bui MM, Lloyd MC, Abrahams D, Huynh AS, et al. A mammaglobin-A targeting agent for nonin-vasive detection of breast cancer metastasis in lymph nodes. Cancer Res 2011; 71(3): 1050‒9.
Rehman F, Nagi AH, Hussain M. Immunohistochemical ex-pression and correlation of mammaglobin with the grading sys-tem of breast carcinoma. Indian J Pathol Microbiol 2010; 53(4): 619‒23.
Bhargava R, Beriwal S, Dabbs DJ. Mammaglobin vs GCDFP-15: an immunohistologic validation survey for sensitivity and specificity. Am J Clin Pathol 2007; 127(1): 103‒13.
O'Brien NA, O'Donovan N, Ryan B, Hill AD, McDermott E, O'Higgins N, et al. Mammaglobin a in breast cancer: existence of multiple molecular forms. Int J Cancer 2005; 114(4): 623‒7.
Guan XF, Hamedani MK, Adeyinka A, Walker C, Kemp A, Murphy LC, et al. Relationship between mammaglobin expres-sion and estrogen receptor status in breast tumors. Endocrine. 2003; 21(3): 245‒50.
Chen G, Gharib TG, Huang CC, Taylor JM, Misek DE, Kardia SL, et al. Discordant protein and mRNA expression in lung adenocarcinomas. Mol Cell Proteomics 2002; 1(4): 304‒13.
Wei C, Luo Q, Sun X, Li D, Song H, Li X, et al. MicroRNA-497 induces cell apoptosis by negatively regulating Bcl-2 pro-tein expression at the posttranscriptional level in human breast cancer. Int J Clin Exp Pathol 2015; 8(7): 7729‒39.
Vasudevan D, Hickok JR, Bovee RC, Pham V, Mantell LL, Bah-roos N, et al. Nitric Oxide Regulates Gene Expression in Can-cers by Controlling Histone Posttranslational Modifications. Cancer Res 2015; 75(24): 5299‒308.
Marchetti A, Buttitta F, Bertacca G, Zavaglia K, Bevilacqua G, An-gelucci D, et al. mRNA markers of breast cancer nodal metasta-ses: comparison between mammaglobin and carcinoembryonic antigen in 248 patients. J Pathol 2001; 195(2): 186‒90.
Marques AR, Teixeira E, Diamond J, Correia H, Santos S, Neto L, et al. Detection of human mammaglobin mRNA in serial peripheral blood samples from patients with non-metastatic breast cancer is not predictive of disease recurrence. Breast Cancer Res Treat 2009; 114(2): 223‒32.
Fortunato L, Mascaro A, Baldi A, Farina M, Cortese G, Ventrone MA, et al. Positive bone marrow biopsy is associated with a decreased disease-free survival in patients with operable breast cancer. Ann Surg Oncol 2009; 16(11): 3010‒9.
Lee GW, Kim JY, Koh EH, Kang D, Choi DS, Maeng KY, et al. Plasma human mammaglobin mRNA associated with poor outcome in patients with breast cancer. Genet Mol Res 2012; 11(4): 4034-42.
Al Joudi FS. Human mammaglobin in breast cancer: a brief re-view of its clinical utility. Indian J Med Res 2014; 139(5): 675‒85.